{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:40:03Z","timestamp":1749706803049,"version":"3.41.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of Review<\/jats:title>\n            <jats:p>This review critically examines the clinical utility, efficacy, and tolerability of fluphenazine long-acting injectable (LAI) relative to contemporary alternatives. It further evaluates whether fluphenazine LAI confers substantive advantages over other available formulations for the management of schizophrenia, particularly in light of its long-standing use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>The extant literature demonstrates that the tolerability and side effect profile of fluphenazine LAI are comparable to other FGA LAIs but likely less favorable than available second-generation antipsychotic (SGA) LAIs. Although fluphenazine trends towards the higher end of the efficacy scale in meta-analyses, there is a lack of robust evidence showing a true statistical superiority for relapse prevention in schizophrenia. Social determinants of health (SDoH), such as race and economic factors, significantly influence its prescribing patterns.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Fluphenazine LAI continues to be utilized primarily due to its low cost and widespread clinical familiarity rather than evidence-based superiority in efficacy or tolerability. Its prescribing is disproportionately influenced by healthcare inequities and resource limitations. Clinicians should employ a rigorous, individualized approach to antipsychotic selection, incorporating shared decision-making and patient education to ensure optimal therapeutic outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11920-025-01610-y","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T02:05:43Z","timestamp":1745805943000},"page":"408-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Should we be Prescribing Fluphenazine Long-Acting Injectable Formulation?"],"prefix":"10.1007","volume":"27","author":[{"given":"Dustin","family":"Rowland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Matar HE, Almerie MQ, Sampson SJ. Fluphenazine (oral) versus placebo for schizophrenia. Cochrane Database Syst Rev. 2018;6.","key":"1610_CR1","DOI":"10.1002\/14651858.CD006352.pub3"},{"key":"1610_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jpsychires.2022.12.044","volume":"158","author":"E Groenendaal","year":"2023","unstructured":"Groenendaal E, Lynch S, Dornbush R, Klepacz L, Ferrando S. Clinical determinants, patterns and outcomes of antipsychotic medication prescribing in the treatment of schizophrenia and schizoaffective disorder: a naturalistic cohort study. J Psychiatr Res. 2023;158:273\u201380.","journal-title":"J Psychiatr Res"},{"unstructured":"Ayd FJ. The depot fluphenazines: a reappraisal after 10 years\u2019 clinical experience. Am J Psychiatry. 1975132(5):491\u2013500. https:\/\/psycnet.apa.org\/doi\/10.1176\/ajp.132.5.491","key":"1610_CR3"},{"key":"1610_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11920-010-0121-y","volume":"12","author":"SJ Siegel","year":"2010","unstructured":"Siegel SJ. Resurgence of long-acting antipsychotic formulations. Curr Psychiatry Rep. 2010;12:276\u20138.","journal-title":"Curr Psychiatry Rep"},{"doi-asserted-by":"crossref","unstructured":"Sampford JR, Sampson S, Li BG, Zhao S, Xia J, Furtado VA. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2016;7.","key":"1610_CR5","DOI":"10.1002\/14651858.CD010832.pub2"},{"issue":"3","key":"1610_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1600-0447.1970.tb02115.x","volume":"46","author":"U Malm","year":"1970","unstructured":"Malm U. Intramuscular long-acting fluphenazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1970;46(3):225\u201337.","journal-title":"Acta Psychiatr Scand"},{"unstructured":"Siragusa S, Bistas KG, Saadabadi A. Fluphenazine. 2017.","key":"1610_CR7"},{"unstructured":"Adams CE, Eisenbruch M. Depot fluphenazine for schizophrenia. Cochrane Database Syst Rev. 2000;2.","key":"1610_CR8"},{"unstructured":"Long-acting injectable antipsychotics. A primer. The Carlat Report. Available from: https:\/\/www.thecarlatreport.com\/articles\/1700-long-acting-injectable-antipsychotics-a-primer. Accessed July 27, 2024.","key":"1610_CR9"},{"issue":"3","key":"1610_CR10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/npr2.12251","volume":"42","author":"M Kamali","year":"2022","unstructured":"Kamali M, Zarghami M, Azizi M, Elyasi F. Fluphenazine decanoate-induced bradycardia: a case report. Neuropsychopharmacol Rep. 2022;42(3):368\u201373.","journal-title":"Neuropsychopharmacol Rep"},{"unstructured":"Centers for Medicare & Medicaid Services. National Average Drug Acquisition Cost (NADAC) for outpatient drugs. 2025 Apr 14. Available from: https:\/\/data.medicaid.gov\/","key":"1610_CR11"},{"issue":"6","key":"1610_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2125.1979.tb01045.x","volume":"8","author":"DH Wiles","year":"1979","unstructured":"Wiles DH, Gelder MG. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate. Br J Clin Pharmacol. 1979;8(6):565\u201370.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1610_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00431778","volume":"87","author":"SS Chang","year":"1985","unstructured":"Chang SS, Javaid JI, Dysken MW, Casper RC, Janicak PG, Davis JM. Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia. Psychopharmacology. 1985;87(1):55\u20138.","journal-title":"Psychopharmacology"},{"issue":"4","key":"1610_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1055\/s-0041-1723921","volume":"9","author":"NR Schooler","year":"1976","unstructured":"Schooler NR, Levine J, NIMH-PRB Collaborative Fluphenazine Study Group. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. Pharmacopsychiatry. 1976;9(4):159\u201369.","journal-title":"Pharmacopsychiatry"},{"key":"1610_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1017\/9781009002103.011","volume-title":"The clinical use of antipsychotic plasma levels","author":"JM Meyer","year":"2021","unstructured":"Meyer JM, Stahl SM. Fluphenazine and fluphenazine decanoate. The clinical use of antipsychotic plasma levels. Cambridge: Cambridge University Press; 2021. pp. 174\u201389."},{"issue":"3","key":"1610_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.9740\/mhc.2023.06.147","volume":"13","author":"JT Tran","year":"2023","unstructured":"Tran JT, Binger KJ, Miles TM. Assessment of oral overlap with antipsychotic long-acting injectables initiated in an inpatient setting. Mental Health Clinician. 2023;13(3):147\u201351.","journal-title":"Mental Health Clinician"},{"doi-asserted-by":"crossref","unstructured":"Edinoff AN, Armistead G, Rosa CA, Anderson A, Patil R, Cornett EM et al. Phenothiazines and their evolving roles in clinical practice: A narrative review. Health Psychol Res. 2022;10(4).","key":"1610_CR17","DOI":"10.52965\/001c.38930"},{"issue":"7","key":"1610_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1254\/fpj.74.871","volume":"74","author":"PC Chen","year":"1978","unstructured":"Chen PC. Pharmacological studies of long-acting phenothiazines with particular reference to fluphenazine decanoate (author\u2019s transl). Nihon Yakurigaku Zasshi Folia Pharmacol Jpn. 1978;74(7):871\u201383.","journal-title":"Nihon Yakurigaku Zasshi Folia Pharmacol Jpn"},{"issue":"Suppl 3","key":"1610_CR19","doi-asserted-by":"publisher","first-page":"21984","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):21984.","journal-title":"J Clin Psychiatry"},{"doi-asserted-by":"crossref","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, Meht\u00e4l\u00e4 J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686\u201393.","key":"1610_CR20","DOI":"10.1001\/jamapsychiatry.2017.1322"},{"issue":"1","key":"1610_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1192\/pb.bp.114.049171","volume":"41","author":"PM Haddad","year":"2017","unstructured":"Haddad PM, Olajide D. Comparison of the effectiveness of depot antipsychotics in routine clinical practice. Psychiatr Bull. 2017;41(1):19\u201324. https:\/\/doi.org\/10.1192\/pb.bp.114.049171.","journal-title":"Psychiatr Bull"},{"key":"1610_CR22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2147\/NDT.S390482","volume":"19","author":"N Yasui-Furukori","year":"2023","unstructured":"Yasui-Furukori N, Kawamata Y, Sasaki T, Yokoyama S, Okayasu H, Shinozaki M, et al. Prescribing trends for the same patients with schizophrenia over 20 years. Neuropsychiatr Dis Treat. 2023;19:921\u20138.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1610_CR23","doi-asserted-by":"publisher","first-page":"621691","DOI":"10.3389\/fphar.2021.621691","volume":"12","author":"AR Eugene","year":"2021","unstructured":"Eugene AR, Eugene B, Masiak M, Masiak JS. Head-to-head comparison of sedation and somnolence among 37 antipsychotics in schizophrenia, bipolar disorder, major depression, autism spectrum disorders, delirium, and repurposed in COVID-19, infectious diseases, and oncology from the FAERS, 2004\u20132020. Front Pharmacol. 2021;12:621691.","journal-title":"Front Pharmacol"},{"doi-asserted-by":"crossref","unstructured":"Dold M, Samara MT, Li C, Tardy M, Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst Rev. 2015;1.","key":"1610_CR24","DOI":"10.1002\/14651858.CD009831.pub2"},{"doi-asserted-by":"crossref","unstructured":"Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J et al. Fluphenazine decanoate (depot) and Enanthate for schizophrenia. Cochrane Database Syst Rev. 2015;2.","key":"1610_CR25","DOI":"10.1002\/14651858.CD000307.pub2"},{"issue":"9209","key":"1610_CR26","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","volume":"355","author":"JG Reilly","year":"2000","unstructured":"Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355(9209):1048\u201352.","journal-title":"Lancet"},{"issue":"5","key":"1610_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jaclp.2021.02.003","volume":"62","author":"MC Funk","year":"2021","unstructured":"Funk MC, Cates KW, Rajagopalan A, Lane CE, Lou J. Assessment of QTc and risk of Torsades de pointes in ventricular conduction delay and pacing: a review of the literature and call to action. J Acad Consult Liaison Psychiatry. 2021;62(5):501\u201310.","journal-title":"J Acad Consult Liaison Psychiatry"},{"issue":"4","key":"1610_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1176\/appi.focus.18306","volume":"18","author":"M Huhn","year":"2020","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Focus. 2020;18(4):443\u201355.","journal-title":"Focus"},{"issue":"10327","key":"1610_CR29","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","volume":"399","author":"J Schneider-Thoma","year":"2022","unstructured":"Schneider-Thoma J, Chalkou K, D\u00f6rries C, Bighelli I, Ceraso A, Huhn M, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824\u201336.","journal-title":"Lancet"},{"key":"1610_CR30","first-page":"15","volume":"1","author":"B Wistedt","year":"1986","unstructured":"Wistedt B. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. Int Clin Psychopharmacol. 1986;1:15\u201323.","journal-title":"Int Clin Psychopharmacol"},{"key":"1610_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","volume":"237","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Zhang C, Siafis S, Zhuo K, Zhu D, Wu H, Liu D, Jiang K, Wang J, Leucht S, Li C. Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis. Schizophr Res. 2021;237:20\u20135.","journal-title":"Schizophr Res"},{"issue":"2","key":"1610_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.pnpbp.2006.10.007","volume":"31","author":"M Jakovljevic","year":"2007","unstructured":"Jakovljevic M, Pivac N, Mihaljevic-Peles A, Mustapic M, Relja M, Ljubicic D, Marcinko D, Muck-Seler D. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):399\u2013402.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"1610_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1192\/bjpo.bp.115.002576","volume":"2","author":"YJ Zhao","year":"2016","unstructured":"Zhao YJ, Lin L, Teng M, Khoo AL, Soh LB, Furukawa TA, et al. Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. BJPsych Open. 2016;2(1):59\u201366.","journal-title":"BJPsych Open"},{"issue":"5","key":"1610_CR34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1176\/appi.ps.202000932","volume":"73","author":"N Bareis","year":"2022","unstructured":"Bareis N, Olfson M, Wall M, Stroup TS. Variation in psychotropic medication prescription for adults with schizophrenia in the united States. Psychiatr Serv. 2022;73(5):492\u2013500.","journal-title":"Psychiatr Serv"},{"issue":"2","key":"1610_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/oxfordjournals.schbul.a006996","volume":"29","author":"J Kreyenbuhl","year":"2003","unstructured":"Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF. Racial disparity in the Pharmacological management of schizophrenia. Schizophr Bull. 2003;29(2):183\u201394.","journal-title":"Schizophr Bull"},{"issue":"1","key":"1610_CR36","doi-asserted-by":"publisher","first-page":"13136","DOI":"10.1038\/s41598-021-92204-0","volume":"11","author":"R \u00c5gren","year":"2021","unstructured":"\u00c5gren R. Worldwide antipsychotic drug search intensities: Pharmacoepidemological estimations based on Google trends data. Sci Rep. 2021;11(1):13136.","journal-title":"Sci Rep"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-025-01610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-025-01610-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-025-01610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:12:22Z","timestamp":1749705142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11920-025-01610-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1007\/s11920-025-01610-y","relation":{},"ISSN":["1535-1645"],"issn-type":[{"type":"electronic","value":"1535-1645"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"17 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}